Yahoo
NasdaqGM - Nasdaq Real Time Price USD

ARS Pharmaceuticals, Inc. (SPRY)

3.3800 -0.2800 (-7.65%)
At close: October 30 at 4:00:00 PM EDT
3.3800 0.0000 (0.00%)
After hours: October 30 at 4:27:10 PM EDT
Trade SPRY on Coinbase
View in AlphaSpace Currency in USD All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
116,927
84,278
89,149
30
1,316
Cost of Revenue
33,477
20,423
977
0
--
Gross Profit
83,450
63,855
88,172
30
--
Operating Expense
299,717
243,303
91,255
67,550
36,832
Operating Income
-216,267
-179,448
-3,083
-67,520
-35,516
Net Non Operating Interest Income Expense
3,150
8,070
11,369
--
--
Other Income Expense
--
--
11,369
13,155
834
Pretax Income
-215,512
-171,378
8,286
-54,365
-34,682
Tax Provision
--
-80
288
0
--
Net Income Common Stockholders
-215,432
-171,298
7,998
-54,365
-34,682
Diluted NI Available to Com Stockholders
-215,432
-171,298
7,998
-54,365
-34,682
Basic EPS
-2.18
-1.74
0.08
-0.57
-0.87
Diluted EPS
-2.18
-1.74
0.08
-0.57
-0.87
Basic Average Shares
99,112.7200
98,566.4810
96,936.6610
95,215.3220
39,956.0430
Diluted Average Shares
99,112.7200
98,566.4810
102,390.8280
95,215.3220
39,956.0430
Total Operating Income as Reported
-216,267
-179,448
-3,083
-67,520
-35,516
Total Expenses
333,194
263,726
92,232
67,550
36,832
Net Income from Continuing & Discontinued Operation
-215,432
-171,298
7,998
-54,365
-34,682
Normalized Income
-215,432
-171,298
7,998
-54,365
-34,542
Interest Income
--
10,669
11,369
--
--
Interest Expense
7,519
2,599
0
--
--
Net Interest Income
3,150
8,070
11,369
--
--
EBIT
-207,993
-168,779
8,286
-67,520
-35,516
EBITDA
-207,993
-168,779
8,286
-67,520
-35,197
Reconciled Cost of Revenue
33,477
20,423
977
0
--
Reconciled Depreciation
-2,114
-4,156
-7,175
-6,775
319
Net Income from Continuing Operation Net Minority Interest
-215,432
-171,298
7,998
-54,365
-34,682
Total Unusual Items Excluding Goodwill
--
--
--
--
-140
Total Unusual Items
--
--
--
--
-140
Normalized EBITDA
-207,993
-168,779
8,286
-67,520
-35,057
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2022 - 12/4/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: